TYRA-200

TYRA-200 is a potent and orally active FGFR2 inhibitor. TYRA-200 inhibits the kinase activity of wild-type FGFR2 and its mutants. TYRA-200 induces significant tumor regression in FGFR2-driven cancer models. TYRA-200 can be used for the research of FGFR2-altered advanced solid tumors, intrahepatic cholangiocarcinoma, and endometrial cancer.


Cat. No.: EX-A13990	Purity: >98%

	Chemical structure of TYRA-200

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
25mg	646	in_stock
50mg	1028	in_stock
100mg	1439	in_stock
250mg	2034	in_stock
500mg	2709	in_stock

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


Synonyms	TYRA 200
CAS No.	2823289-77-4
Purity	>98%
Formula	C23H24FN7O2
Mol Weight	449.4808
Color	Off-white to light yellow
State	Solid
Solubility	DMSO : 100 mg/mL
Shelf Life	>3 years if stored properly
Storage	Powder -20°C, 3 years , 4°C, 2 years; In solvent -20°C, 1 month.
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Rodon Ahnert J, et al. A multicenter, open-label, first-in-human study of TYRA-200 in advanced intrahepatic cholangiocarcinoma and other solid tumors with activating FGFR2 gene alterations (SURF201). J Clin Oncol. 2025;43(4 suppl):TPS646. doi: 10.1200/JCO.2025.43.4.suppl.TPS646 [2]. Allen E, et al. TYRA-200: Potent Against FGFR2 Fusions, Molecular Brake Mutations and Gatekeeper Resistance. Eur J Cancer. 2022;174 Suppl 1:S16.
CoA	CoA of TYRA-200

Smiles:	C=CC(NC1=CC2=C(N(C=C2C)C3=C(C=NC(NC4=CN(N=C4)CC(C)(O)C)=N3)F)C=C1)=O


		Search